SG11202110092PA - Macrocyclic azolopyridine derivatives as eed and prc2 modulators - Google Patents
Macrocyclic azolopyridine derivatives as eed and prc2 modulatorsInfo
- Publication number
- SG11202110092PA SG11202110092PA SG11202110092PA SG11202110092PA SG11202110092PA SG 11202110092P A SG11202110092P A SG 11202110092PA SG 11202110092P A SG11202110092P A SG 11202110092PA SG 11202110092P A SG11202110092P A SG 11202110092PA SG 11202110092P A SG11202110092P A SG 11202110092PA
- Authority
- SG
- Singapore
- Prior art keywords
- azolopyridine
- prc2
- eed
- macrocyclic
- modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Telescopes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819064P | 2019-03-15 | 2019-03-15 | |
| PCT/US2020/022724 WO2020190754A1 (en) | 2019-03-15 | 2020-03-13 | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110092PA true SG11202110092PA (en) | 2021-10-28 |
Family
ID=70228838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110092PA SG11202110092PA (en) | 2019-03-15 | 2020-03-13 | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10973805B2 (en) |
| EP (1) | EP3938050A1 (en) |
| JP (1) | JP7549597B2 (en) |
| KR (1) | KR20210151833A (en) |
| CN (1) | CN114144230B (en) |
| AU (1) | AU2020241254A1 (en) |
| BR (1) | BR112021018238A2 (en) |
| CA (1) | CA3133751A1 (en) |
| IL (1) | IL286433A (en) |
| MX (1) | MX2021011118A (en) |
| SG (1) | SG11202110092PA (en) |
| TW (1) | TWI845638B (en) |
| WO (1) | WO2020190754A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
| EP3938050A1 (en) * | 2019-03-15 | 2022-01-19 | Fulcrum Therapeutics, Inc. | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| CN117396483A (en) * | 2021-04-02 | 2024-01-12 | 弗尔康医疗公司 | Macrocyclic azolopyridines |
| WO2022212748A1 (en) * | 2021-04-02 | 2022-10-06 | Fulcrum Therapeutics, Inc. | Polymorphic forms of (s)-12-fluoro-4-(1-methyl-1h-pyrazol-5-yl)-7a,8,13,14-tetrahydro-7h-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine |
| CN115490708A (en) * | 2021-06-18 | 2022-12-20 | 苏州亚盛药业有限公司 | Sulfonamide macrocyclic derivatives, and preparation method and application thereof |
| WO2023049724A1 (en) * | 2021-09-24 | 2023-03-30 | Oric Pharmaceuticals, Inc. | Prc2 inhibitors for use in treating blood disorders |
| WO2023049723A1 (en) * | 2021-09-24 | 2023-03-30 | Oric Pharmaceuticals, Inc. | Prc2 inhibitors for use in treating blood disorders |
| WO2023192415A1 (en) * | 2022-03-29 | 2023-10-05 | Fulcrum Therapeutics, Inc. | An embryonic ectoderm development inhibitor for the treatment of sickle cell disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| TWI496779B (en) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | Triazolopyridine compounds as pim kinase inhibitors |
| EP2331543A4 (en) | 2008-09-26 | 2013-06-19 | Agency Science Tech & Res | 3-deazaneplanocin derivatives |
| EP2760452A4 (en) * | 2011-09-30 | 2015-04-01 | Glaxosmithkline Llc | Methods of treating cancer |
| UA114414C2 (en) | 2011-11-03 | 2017-06-12 | Мілленніум Фармасьютікалз, Інк. | INTRODUCTION OF NEDD8 ACTIVATING ENZYME INHIBITOR AND HYPOMETILING AGENT |
| KR102534028B1 (en) | 2014-12-23 | 2023-05-19 | 노파르티스 아게 | Triazolopyrimidine compounds and uses thereof |
| CN109790166A (en) * | 2016-06-20 | 2019-05-21 | 诺华股份有限公司 | Imidazopyridine is used for treating cancer |
| EP3472168B1 (en) | 2016-06-20 | 2024-01-10 | Novartis AG | Crystalline forms of triazolopyrimidine compound |
| CN109906224B (en) * | 2016-06-20 | 2022-02-25 | 诺华股份有限公司 | Triazolopyridine compounds and uses thereof |
| US11624068B2 (en) | 2016-07-15 | 2023-04-11 | Tufts Medical Center, Inc. | Compositions and methods for improving immune system function |
| WO2018140934A1 (en) | 2017-01-30 | 2018-08-02 | The Children's Hospital Of Philadelphia | Compositions and methods for hemoglobin production |
| AU2018251687B2 (en) | 2017-04-10 | 2021-07-29 | The Regents Of The University Of Michigan | Covalent small molecule DCN1 inhibitors and therapeutic methods using the same |
| US20190055264A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| AU2019384547A1 (en) | 2018-11-20 | 2021-06-03 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease |
| EP3938050A1 (en) | 2019-03-15 | 2022-01-19 | Fulcrum Therapeutics, Inc. | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| CN117396483A (en) | 2021-04-02 | 2024-01-12 | 弗尔康医疗公司 | Macrocyclic azolopyridines |
| WO2022212748A1 (en) | 2021-04-02 | 2022-10-06 | Fulcrum Therapeutics, Inc. | Polymorphic forms of (s)-12-fluoro-4-(1-methyl-1h-pyrazol-5-yl)-7a,8,13,14-tetrahydro-7h-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine |
| WO2022232435A1 (en) | 2021-04-29 | 2022-11-03 | Fulcrum Therapeutics, Inc. | Methods of regulating bcl11a expression and treatment of bcl11a-mediated disorders |
-
2020
- 2020-03-13 EP EP20718058.9A patent/EP3938050A1/en active Pending
- 2020-03-13 WO PCT/US2020/022724 patent/WO2020190754A1/en active Application Filing
- 2020-03-13 CA CA3133751A patent/CA3133751A1/en active Pending
- 2020-03-13 MX MX2021011118A patent/MX2021011118A/en unknown
- 2020-03-13 AU AU2020241254A patent/AU2020241254A1/en active Pending
- 2020-03-13 JP JP2021555455A patent/JP7549597B2/en active Active
- 2020-03-13 BR BR112021018238A patent/BR112021018238A2/en unknown
- 2020-03-13 KR KR1020217033290A patent/KR20210151833A/en unknown
- 2020-03-13 CN CN202080033787.5A patent/CN114144230B/en active Active
- 2020-03-13 TW TW109108410A patent/TWI845638B/en active
- 2020-03-13 SG SG11202110092PA patent/SG11202110092PA/en unknown
- 2020-04-24 US US16/858,404 patent/US10973805B2/en active Active
-
2021
- 2021-02-18 US US17/178,637 patent/US11590111B2/en active Active
- 2021-09-14 IL IL286433A patent/IL286433A/en unknown
-
2022
- 2022-12-20 US US18/085,134 patent/US12109198B2/en active Active
-
2023
- 2023-04-27 US US18/140,527 patent/US20240075016A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210151833A (en) | 2021-12-14 |
| US11590111B2 (en) | 2023-02-28 |
| CA3133751A1 (en) | 2020-09-24 |
| US20240139163A1 (en) | 2024-05-02 |
| CN114144230A (en) | 2022-03-04 |
| EP3938050A1 (en) | 2022-01-19 |
| WO2020190754A1 (en) | 2020-09-24 |
| TW202102495A (en) | 2021-01-16 |
| AU2020241254A1 (en) | 2021-10-07 |
| US20220160686A1 (en) | 2022-05-26 |
| US20240075016A1 (en) | 2024-03-07 |
| IL286433A (en) | 2021-10-31 |
| US12109198B2 (en) | 2024-10-08 |
| CN114144230B (en) | 2024-04-23 |
| BR112021018238A2 (en) | 2021-12-28 |
| MX2021011118A (en) | 2022-01-18 |
| US10973805B2 (en) | 2021-04-13 |
| US20200360353A1 (en) | 2020-11-19 |
| TWI845638B (en) | 2024-06-21 |
| JP2022525199A (en) | 2022-05-11 |
| JP7549597B2 (en) | 2024-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286433A (en) | Macrocyclic azolopyridine derivatives as eed and prc2 modulators | |
| IL286846A (en) | Camptothecin derivatives | |
| IL271964A (en) | Macrocyclic compounds and uses thereof | |
| EP3454324A4 (en) | Gamma adjustment method and apparatus | |
| EP3478171A4 (en) | Bio-adaptable implantable sensor apparatus and methods | |
| EP3302361A4 (en) | Capsular tension ring inserter and method | |
| EP3661513A4 (en) | Organophosphate derivatives | |
| EP3536698A4 (en) | Lanosterol prodrug compound and preparation method therefor and use thereof | |
| EP3426242A4 (en) | Icariin and icaritin derivatives | |
| IL288991A (en) | Macrocyclic compound and uses thereof | |
| GB201506116D0 (en) | Kit and combination therapy for nausea and vomiting | |
| EP3360531A4 (en) | Kit preparation and dose adjustment method | |
| EP3584459A4 (en) | Tapered roller bearing | |
| EP4037670A4 (en) | 5-fluoronicotinamide derivatives and uses thereof | |
| EP3590929A4 (en) | Spiro compound and use thereof | |
| EP3681491A4 (en) | Methods for making and using endoxifen | |
| EP3604841A4 (en) | Tapered roller bearing | |
| IL285074A (en) | Gpr35 modulators | |
| EP3353341A4 (en) | Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same | |
| EP3611393A4 (en) | Tapered roller bearing | |
| EP3587847A4 (en) | Conical roller bearing | |
| EP3316487A4 (en) | Interference reduction method and apparatus | |
| EP3402479A4 (en) | Composition containing artesunate | |
| EP3690265A4 (en) | Conical roller bearing | |
| EP3503667A4 (en) | Signal acquisition method and apparatus |